COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression
September 06, 2023 04:00 ET
|
COMPASS Pathways
LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
COMPASS Pathways to participate in upcoming September investor conferences
August 29, 2023 16:30 ET
|
COMPASS Pathways
LONDON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors
August 16, 2023 08:58 ET
|
COMPASS Pathways
Transaction led by healthcare specialist investors, TCGX and Aisling Capital $125 million financing upfront with up to an additional $160 million tied to exercise of warrants Net proceeds...
COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights
August 03, 2023 07:00 ET
|
COMPASS Pathways
LONDON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Highlights: COMP360 Phase 3 pivotal program ongoing and on trackCPT® III code for in-person psychedelic therapy support accepted by the American Medical...
COMPASS Pathways plc to announce second quarter 2023 financial results on August 3, 2023
July 31, 2023 08:32 ET
|
COMPASS Pathways
LONDON, July 31, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine
July 25, 2023 04:00 ET
|
COMPASS Pathways
LONDON, July 25, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology
July 17, 2023 04:00 ET
|
COMPASS Pathways
Results of COMPASS Pathways’ open-label study of COMP360 psilocybin treatment, alongside SSRI antidepressants, suggest that SSRIs do not interfere with the potential therapeutic effect of COMP360 ...
Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psilocybin
July 13, 2023 04:00 ET
|
COMPASS Pathways
Leading psychiatrists and researchers examine common assumptions about the term “psychedelic-assisted psychotherapy” and the role of psychotherapy when evaluating psilocybin treatment.Authors...
American Medical Association Releases Language of First New Current Procedural Terminology Code for Psychedelic Therapies
July 06, 2023 07:00 ET
|
COMPASS Pathways
New code will facilitate reimbursement for psychedelic therapy in the US, if approvedCOMPASS Pathways to hold webinar on new code on Tuesday, July 11, 8:00 am EDT (1:00 pm BST) LONDON, July 06, 2023...
COMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital
July 05, 2023 07:00 ET
|
COMPASS Pathways
LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today...